Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.

Artur Menegaz de AlmeidaMarianna LeiteLucca Moreira LopesPedro Gomes LimaMaria Luísa Siegloch BarrosSamuel Rocha PinheiroÍtalo AndradePatrícia VianaVictória MorbachGabriel MarinheiroRicardo de OliveiraAgostinho C Pinheiro

Published in: Expert review of neurotherapeutics (2024)

In this meta-analysis, consistent results suggest that gantenerumab is not safe and efficient for early AD, showing no improvement in clinical scores for AD and being associated with the occurrence of ARIA-E and ARIA-H.

Keyphrases

systematic review
risk assessment
meta analyses
cognitive decline
randomized controlled trial